Big Tobacco’s $1.2B Bet On Zyn

As federal leaders bicker and stumble, a tobacco giant is quietly betting $1.2 billion that America’s nicotine habit — and our regulators — will keep Zyn’s boom going.

Story Snapshot

Philip Morris International is doubling its Aurora, Colorado Zyn campus investment from $600 million to about $1.2 billion, citing rapid U.S. demand for nicotine pouches.
The Aurora plant makes Zyn nicotine pouches for American buyers and for export to Asia, Latin America, and the Caribbean, and is expected to generate about $550 million a year in economic activity.
Zyn shipments in the United States have exploded, rising to more than 200 million cans in a single quarter and driving growth in Philip Morris International’s smoke-free business.
The expansion follows federal Food and Drug Administration (FDA) authorization for 20 Zyn products to be marketed as less harmful than cigarettes, even as public-health groups warn about youth use and long-term risks.

Big Money Flows Into Aurora’s Zyn Factory

Philip Morris International, the global cigarette and nicotine company, now plans to spend about **$1.2 billion** on its Zyn manufacturing campus in Aurora, Colorado, through 2028. This is double the original **$600 million** plan the company announced in 2024, a sign of how quickly Zyn sales have grown and how strongly the firm believes that growth will continue. The Aurora campus recently opened and has started producing Zyn nicotine pouches for the American market.

The company says the Aurora site makes Zyn pouches both for buyers in the United States and for export to regions such as Asia, Latin America, and the Caribbean. Philip Morris International projects that once the campus is fully up and running, it will generate around **$550 million** in yearly economic activity and support about **1,000 indirect jobs**, on top of hundreds of direct factory positions. Officials in Colorado have supported the plant with tax credits, hoping these jobs will help local workers and businesses.

Zyn’s Rapid Growth and the Shift Away From Cigarettes

Zyn is a small oral nicotine pouch that contains no tobacco leaf, and it has become Philip Morris International’s fastest-growing product line in the United States. The company’s own data show that U.S. shipments of Zyn have risen sharply, reaching about **202 million cans in the first quarter of 2025**, up more than 50 percent from a year before. Philip Morris International now expects to ship roughly **800 to 840 million cans** of Zyn in 2025, far above earlier forecasts. This surge has led to shortages and pushed the company to race ahead with new factories.

Philip Morris International executives say smoke-free products, including Zyn pouches and IQOS heated-tobacco devices, are now central to the business and to its future profits. Net revenue from smoke-free products has been rising while sales of traditional combustible cigarettes are flat or declining in some markets. Investors have rewarded this shift, with company leaders telling them that Zyn’s rapid expansion has helped raise profit margins and support a higher share price over the last two years. For many Americans, this looks like another example of a huge corporation cashing in while Washington struggles to manage basic health and economic policy.

FDA’s Role and Health Concerns Behind the Boom

Supporters of Zyn point to a key federal step: the **Food and Drug Administration (FDA)** recently authorized 20 Zyn nicotine-pouch products as “modified-risk” tobacco products. This allows Philip Morris International to tell adult smokers that these pouches expose them to fewer harmful chemicals than regular cigarettes, as long as the company follows strict marketing rules. However, the FDA has not said Zyn is safe; the agency stresses that reduced-risk does not mean no risk, and nicotine itself remains addictive.

Philip Morris International inaugurated a $1.2 billion manufacturing campus in Aurora, Colorado, to expand production of its Zyn nicotine pouches, doubling its original investment plan of $600 million amid rising demand for smoke-free products. The 780,000-square-foot facility,… pic.twitter.com/R3IdolPIRA

— Traded: Venture Capital (@TradedVC) July 28, 2026

Public-health groups and some local residents are uneasy with the pace of the expansion, especially in communities near the new factories. Experts worry that colorful flavors and online hype could pull in teenagers and young adults, turning nicotine pouches into a new gateway to addiction. They argue that the same federal government that struggles to control opioids and vaping is now allowing a rapid build-out of another nicotine industry, backed by billion-dollar investments and powerful lobbying. This deepens the feeling among many Americans that regulators and lawmakers listen more to corporate balance sheets than to families.

Jobs, Local Benefits, and Questions About Who Really Wins

Philip Morris International promotes the Aurora campus as proof that it is “invested in America,” promising **about 500 direct jobs** and strong ripple effects for local suppliers. Governor Jared Polis and other state leaders have welcomed the project, pointing to tax incentives and the promise of new middle-income positions in a region facing rising costs of living. For residents who feel shut out of the tech boom and squeezed by inflation, a steady factory job can look like a much-needed opportunity, even if it comes from a tobacco company.

At the same time, the numbers raise hard questions that go beyond party lines. Zyn’s growth shows how quickly addiction-based products can scale when big money and weak national focus meet. Conservatives and liberals alike who doubt “deep state” regulators see a pattern: the federal government struggles to keep up, while multinational companies build plants, shape the science narrative, and lock in profits. In Aurora and across the country, the debate is not just about pouches versus cigarettes. It is about who sets the rules for health and work in America — and whether ordinary citizens ever truly get to decide.